Modelling the lifetime economic consequences of glaucoma in France.

abstract：AIM:Disease-modifying therapies (DMTs) impact the natural history of relapsing forms of multiple sclerosis (RRMS) by reducing annual relapse rates and slowing disability progression. The effect of DMTs on indirect costs has not been consistently explored in cost-effectiveness studies thus far. The value to patients of ...

journal_title：Journal of medical economics

authors： Frasco MA,Shih T,Incerti D,Diaz Espinosa O,Vania DK,Thomas N

更新日期：2017-10-01 00:00:00

abstract：:Aim: To estimate the cost-effectiveness of atezolizumab compared with docetaxel and nivolumab for the treatment of advanced non-small cell lung cancer (NSCLC), as a second-line treatment, in a French setting.Materials and methods: A three-state partitioned-survival model was developed (progression-free survival, post-...

journal_title：Journal of medical economics

authors： Marine S,Stéphane R,Nicolas P,Felizzi F,Paracha N,Benjamin M,Perol M

更新日期：2020-05-01 00:00:00

abstract：BACKGROUND:Percutaneous pulmonary valve implantation (PPVI) using the Melody * transcatheter pulmonary valve is a new procedure introduced in 2000 as a less invasive treatment for right ventricular outflow tract (RVOT) dysfunction. The aim of this new procedure is to restore pulmonary valve competence without the need ...

journal_title：Journal of medical economics

authors： Raikou M,McGuire A,Lurz P,Bonhoeffer P,Wegmueller Y

更新日期：2011-01-01 00:00:00

abstract：OBJECTIVES:This study examines the epidemiology and economic impact of chronic obstructive pulmonary disease (COPD) at a nationwide level in South Korea. METHODS:This retrospective analysis used the societal cost-of-illness framework, consisting of direct medical costs, direct non-medical costs, and indirect costs. In...

journal_title：Journal of medical economics

authors： Kim J,Lee TJ,Kim S,Lee E

更新日期：2016-01-01 00:00:00

abstract：OBJECTIVE:This study compared real-world treatment patterns and healthcare costs among biologic-naive psoriasis patients initiating apremilast or biologics. METHODS:A retrospective cohort study was conducted using the Optum Clinformatics™ claims database. Patients with psoriasis were selected if they had initiated apr...

journal_title：Journal of medical economics

authors： Wu JJ,Pelletier C,Ung B,Tian M

更新日期：2019-04-01 00:00:00

abstract：:Background: Procedural efficiencies can contribute to cost reductions in transcatheter aortic valve replacement procedures (TAVR). The objective of this study is to determine operating room (OR) variable cost per minute in endovascular TAVR procedures, in a real-world hospital setting. Methods: Using Premier data from...

journal_title：Journal of medical economics

authors： Potter BJ,Ann Thompson C

更新日期：2019-10-01 00:00:00

abstract：OBJECTIVE:The aim of this study was to evaluate medication adherence and persistence of patients treated with Etanercept and Adalimumab for Rheumatoid Arthritis, also giving economic evaluations on therapy costs for Received Daily Dose (RDD). MATERIALS AND METHODS:This retrospective study took into account 6 years fro...

journal_title：Journal of medical economics

authors： Santoleri F,Sorice P,Lasala R,Rizzo RC,Costantini A

更新日期：2014-05-01 00:00:00

abstract：OBJECTIVES:Two anti-cancer drugs are currently approved for the treatment of HER2-positive metastatic breast cancer (MBC): trastuzumab-based therapy (TBT) administered intravenously as first line therapy until disease progression and lapatinib, an oral self-administered dual therapy with capecitabine (L+C) as second in...

journal_title：Journal of medical economics

authors： Benjamin L,Buthion V,Iskedjian M,Farah B,Rioufol C,Vidal-Trécan G

更新日期：2013-01-01 00:00:00

abstract：OBJECTIVES:To describe treatment patterns and healthcare burden among individuals with suspected pulmonary arterial hypertension (PAH), as identified through a practice guideline-based healthcare claims algorithm. METHODS:Adults with evidence of PAH from 1 January 2004 (commercial and Medicaid) or 1 July 2006 (Medicar...

journal_title：Journal of medical economics

authors： Copher R,Cerulli A,Watkins A,Laura Monsalvo M

更新日期：2012-01-01 00:00:00

abstract：OBJECTIVE:The only effective treatment for severe aortic stenosis (AS) is valve replacement. However, many patients with co-existing conditions are ineligible for surgical valve replacement, historically leaving medical management (MM) as the only option which has a poor prognosis. Transcatheter Aortic Valve Replacemen...

journal_title：Journal of medical economics

authors： Hancock-Howard RL,Feindel CM,Rodes-Cabau J,Webb JG,Thompson AK,Banz K

更新日期：2013-01-01 00:00:00

abstract：OBJECTIVE:A new and smaller percutaneous ventricular assist device (pVAD, Impella, Abiomed, Danvers, MA) has been developed to provide circulatory support in hemodynamically unstable patients and to prevent hemodynamic collapse during high-risk percutaneous coronary interventions (PCI). The objective of the study was t...

journal_title：Journal of medical economics

authors： Roos JB,Doshi SN,Konorza T,Palacios I,Schreiber T,Borisenko OV,Henriques JP

更新日期：2013-01-01 00:00:00

abstract：OBJECTIVE:Allergic rhinitis (AR) is a chronic disease with a substantial clinical and economic burden. This study estimated the potential budget impact (BI) associated with market entry of Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract Tablet for Sublingual Use ('5...

journal_title：Journal of medical economics

authors： Ivanova JI,Kelkar S,King S,Birnbaum HG,Hocker S,Phipps R,Lankow R

更新日期：2015-01-01 00:00:00

abstract：:Objectives: To describe the clinical characteristics, treatment pattern, and medical costs associated with metastatic castration-resistant prostate cancer (mCRPC) in Chinese patients. Methods: This retrospective study identified a group of patients with newly-developed mCRPC from 2012 to 2016 to extract information fr...

journal_title：Journal of medical economics

authors： Qian Z,Wang Y,Tang Z,Ren D,Wang Z,Chen W,Li Z

更新日期：2019-08-01 00:00:00

abstract：BACKGROUND:Global budget (GB) is considered one of the most important payment methods available. Since a new round of healthcare system reforms in 2009, the Chinese government has been paying attention to this prospective payment. However, it is unclear whether GB has influenced cost control and how it works in rural C...

journal_title：Journal of medical economics

authors： He R,Miao Y,Ye T,Zhang Y,Tang W,Li Z,Zhang L

更新日期：2017-09-01 00:00:00

abstract：OBJECTIVE:To assess the cost-effectiveness (CE) of the originator follitropin-α (Gonal-F) in patients undergoing a medically assisted reproduction (MAR) program in comparison to its biosimilars Bemfola and Ovaleap in a French context. METHODS:A CE model was developed for France with a National Health Service (NHS) per...

journal_title：Journal of medical economics

authors： Grynberg M,Murphy C,Doré C,Fresneau L,Paillet S,Petrica N,Frédérique M,Ravonimbola H

更新日期：2018-11-21 00:00:00

abstract：BACKGROUND:Many countries have various requirements for local economic analyses to assess the value of a new health technology and/or to secure reimbursement. This study presents a case study of an economic model developed to assess the cost-effectiveness of posaconazole vs standard azole therapy (fluconazole/itraconaz...

journal_title：Journal of medical economics

authors： Papadopoulos G,Hunt S,Prasad M

更新日期：2013-01-01 00:00:00

abstract：AIM:Renal failure is a growing public health problem, and is mainly treated by hemodialysis. This study aims to estimate the societal costs of hemodialysis in Lebanon. METHODS:This was a quantitative, cross-sectional cost-of-illness study conducted alongside the Nutrition Education for Management of Osteodystrophy tri...

journal_title：Journal of medical economics

authors： Rizk R,Hiligsmann M,Karavetian M,Salameh P,Evers SM

更新日期：2016-12-01 00:00:00

abstract：OBJECTIVE:Basal insulin analogs are well established in the treatment of type 1 diabetes in Germany. However, little is known about their economic impact. The aim of this study for an adult population was to compare, from the perspective of the Statutory Health Insurance (SHI), the cost effectiveness of the long-acting...

journal_title：Journal of medical economics

authors： Pfohl M,Schädlich PK,Dippel FW,Koltermann KC

更新日期：2012-01-01 00:00:00

abstract：INTRODUCTION:Switching drugs from prescription to non-prescription status (Rx-to-OTC) presents a unique set of challenges and opportunities to policy-makers and the industry in terms of managing health outcomes, pharmaceutical spending, and steering of consumer choices of therapy. Decision-analytic models are used to a...

journal_title：Journal of medical economics

authors： Cohen J,Millier A,Karray S,Toumi M

更新日期：2013-01-01 00:00:00

abstract：AIM:This analysis assessed the direct medical costs of newly-diagnosed, temozolomide (TMZ)-treated glioblastoma (GBM) from the perspective of a US commercial setting. MATERIALS AND METHODS:The analysis included subjects identified from the IMS PharMetrics LifeLink Plus™ claims database from January 1, 2008 to August 3...

journal_title：Journal of medical economics

authors： Jiang S,Hill K,Patel D,Waldeck AR,Botteman M,Aly A,Norden AD

更新日期：2017-12-01 00:00:00

abstract：OBJECTIVE:To describe costs, healthcare resource utilization, and adherence of US patients receiving human regular U-500 insulin (U-500R), compared to patients receiving high-dose (>200 units/day) U-100 insulins (U-100) by subcutaneous injection for the treatment of diabetes. METHODS:A retrospective analysis of data f...

journal_title：Journal of medical economics

authors： Eby EL,Wang P,Curtis BH,Xie J,Haldane DC,Idris I,Peters AL,Hood RC,Jackson JA

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:Until recently, standard treatment of venous thromboembolism (VTE) concerned a combination of short-term low-molecular-weight heparin (LMWH) and long-term vitamin-K antagonist (VKA). Risk of bleeding and the requirement for regular anticoagulation monitoring are, however, limiting their use. Rivaroxaban is a...

journal_title：Journal of medical economics

authors： Heisen M,Treur MJ,Heemstra HE,Giesen EBW,Postma MJ

更新日期：2017-08-01 00:00:00

abstract：AIMS:The prevalence of atrial fibrillation (AF) has increased over the past years due to aging of the population, and healthcare costs associated with AF reflect a significant financial burden. The aim of this study was to explore predictors for the real-world AF-related in-hospital costs in patients that recently init...

journal_title：Journal of medical economics

authors： Jacobs MS,van Leent MWJ,Tieleman RG,Jansman FGA,Cao Q,Postma MJ,van Hulst M

更新日期：2017-12-01 00:00:00

abstract：INTRODUCTION:Triple therapy using a protease inhibitor (PI) with peginterferon and ribavirin (PR) is increasingly used in patients with chronic hepatitis C virus (HCV) infection. The most recently introduced PI, simeprevir (SMV), offers high levels of viral eradication combined with a reduced overall duration of therap...

journal_title：Journal of medical economics

authors： Westerhout K,Treur M,Mehnert A,Pascoe K,Ladha I,Belsey J

更新日期：2015-01-01 00:00:00

abstract：OBJECTIVE:In the phase III SECURE trial, isavuconazole was non-inferior to voriconazole for all-cause mortality for the primary treatment of invasive mold disease (IMD) caused by Aspergillus spp. and other filamentous fungi. This analysis assessed whether hospital resource utilization was different between patients tre...

journal_title：Journal of medical economics

authors： Horn D,Goff D,Khandelwal N,Spalding J,Azie N,Shi F,Franks B,Shorr AF

更新日期：2016-07-01 00:00:00

abstract：OBJECTIVE:To assess patient characteristics, treatment patterns, and healthcare resource utilization (HRU)/costs of individuals treated for neuroendocrine tumors (NETs) in the US. METHODS:Using a US administrative claims database, this study identified commercially-insured adults newly diagnosed with carcinoid tumors ...

journal_title：Journal of medical economics

authors： Chuang CC,Bhurke S,Chen SY,Brulais S,Gabriel S

更新日期：2015-02-01 00:00:00

abstract：OBJECTIVES:To compare demographic and comorbidity profiles and healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% (lidocaine patch) versus patients not treated with the lidocaine patch. Repeat comparison for the subset of patients treated in long-term care (LTC) sett...

journal_title：Journal of medical economics

authors： Kirson NY,Ivanova JI,Birnbaum HG,Wei R,Kantor E,Amy Puenpatom R,Ben-Joseph RH,Summers KH

更新日期：2010-01-01 00:00:00

abstract：:Aims: To evaluate costs in patients with diabetes who experienced a macrovascular complication from a Brazilian public healthcare system perspective.Materials and methods: A retrospective, observational study that utilized the database of the Brazilian Unified Health System (DATASUS). Data for direct medical costs (ho...

journal_title：Journal of medical economics

authors： Julian GS,Campos D,Broe Honore J,Sauer Tobaruella F,Hyun Yoon J,Hallén N

更新日期：2020-09-01 00:00:00

abstract：PURPOSE:To evaluate the insulin wastage and associated acquisition costs when switching from individual patient supply (IPS) of 3-mL pens of rapid-acting insulin (RAI) aspart to floor stock (FS) dispensing of 3-mL vials of RAI lispro, and with conversion from IPS of 3-mL pens to centralized unit dose (CUD) of 10-mL via...

journal_title：Journal of medical economics

authors： Kelton KA,Perk S,Loveland S,Perez-Nieves M,Fu H,Peng X

更新日期：2017-05-01 00:00:00

abstract：:Aims: To evaluate total costs and health consequences of a colorectal cancer (CRC) screening program with colonoscopy, fecal immunochemical tests (FIT), and expanded use of multitarget stool DNA (mt-sDNA) from the perspectives of Integrated Delivery Networks (IDNs) and payers in the United States.Materials and methods...

journal_title：Journal of medical economics

authors： Hathway JM,Miller-Wilson LA,Jensen IS,Ozbay B,Regan C,Jena AB,Weinstein MC,Parks PD

更新日期：2020-06-01 00:00:00